Tags

Type your tag names separated by a space and hit enter

Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders.
Neurosci Lett. 2016 Jan 01; 610:223-8.NL

Abstract

Previous studies have indicated that the altered composition of polyunsaturated fatty acids (PUFAs) might contribute to the pathophysiology of autism spectrum disorder (ASD). We examined the relationship between the plasma fatty acid levels, expressed as μg/ml, and the plasma levels of biomarkers of AA-related signaling mediators, such as ceruloplasmin, transferrin and superoxide dismutase, and assessed the behavioral symptoms of 30 individuals with ASD (mean age, 13.6 ± 4.3 years old) compared with 20 age- and gender-matched normal controls (mean age, 13.2 ± 5.4 years old) using Aberrant Behavior Checklists (ABC). The plasma levels of EPA and the plasma ratios of EPA/AA were significantly higher, while the plasma levels of AA and metabolites, such as 5,8,11,14-eicosatetraenoic acid, adrenic acid, and ceruloplasmin (Cp), were significantly lower in the 30 individuals with ASD compared with the 20 normal controls. The ABC scores were significantly increased in the ASD group compared with those of the control group. Thus, the results of the present study revealed that reduced plasma levels of AA and metabolites in association with high plasma EPA/AA ratios might down-regulate AA-related signaling mediators, such as Cp. Subsequently, reduced plasma Cp levels might reduce the protective capacity for brain damage, resulting in the pathophysiology underlying the behavioral symptoms in individuals with ASD. These findings suggest that reduced plasma AA levels may downregulate Cp.

Authors+Show Affiliations

Research Institute of Pervasive Developmental Disorders, Ashiya University, 13-22 Rokurokusocho, Ashiya, 659-8511 Hyogo, Japan. Electronic address: yui16@bell.ocn.ne.jp.Department of Pediatrics, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, 321-0293 Tochigi, Japan.Department of Drug Evaluation and Information, School of Pharmaceutical Science University of Shizuoka, 52-1 Tada, Shizuoka 422-8526, Japan.Department of Drug Evaluation and Information, School of Pharmaceutical Science University of Shizuoka, 52-1 Tada, Shizuoka 422-8526, Japan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26552013

Citation

Yui, Kunio, et al. "Down-regulation of a Signaling Mediator in Association With Lowered Plasma Arachidonic Acid Levels in Individuals With Autism Spectrum Disorders." Neuroscience Letters, vol. 610, 2016, pp. 223-8.
Yui K, Imataka G, Kawasaki Y, et al. Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neurosci Lett. 2016;610:223-8.
Yui, K., Imataka, G., Kawasaki, Y., & Yamada, H. (2016). Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neuroscience Letters, 610, 223-8. https://doi.org/10.1016/j.neulet.2015.11.006
Yui K, et al. Down-regulation of a Signaling Mediator in Association With Lowered Plasma Arachidonic Acid Levels in Individuals With Autism Spectrum Disorders. Neurosci Lett. 2016 Jan 1;610:223-8. PubMed PMID: 26552013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. AU - Yui,Kunio, AU - Imataka,George, AU - Kawasaki,Yohei, AU - Yamada,Hiroshi, Y1 - 2015/11/10/ PY - 2015/10/06/received PY - 2015/11/03/revised PY - 2015/11/04/accepted PY - 2015/11/10/entrez PY - 2015/11/10/pubmed PY - 2016/5/10/medline KW - Arachidonic acid KW - Autism spectrum disorder KW - Competitive interaction KW - Eicosapentaenoic acid KW - Signaling mediators SP - 223 EP - 8 JF - Neuroscience letters JO - Neurosci Lett VL - 610 N2 - Previous studies have indicated that the altered composition of polyunsaturated fatty acids (PUFAs) might contribute to the pathophysiology of autism spectrum disorder (ASD). We examined the relationship between the plasma fatty acid levels, expressed as μg/ml, and the plasma levels of biomarkers of AA-related signaling mediators, such as ceruloplasmin, transferrin and superoxide dismutase, and assessed the behavioral symptoms of 30 individuals with ASD (mean age, 13.6 ± 4.3 years old) compared with 20 age- and gender-matched normal controls (mean age, 13.2 ± 5.4 years old) using Aberrant Behavior Checklists (ABC). The plasma levels of EPA and the plasma ratios of EPA/AA were significantly higher, while the plasma levels of AA and metabolites, such as 5,8,11,14-eicosatetraenoic acid, adrenic acid, and ceruloplasmin (Cp), were significantly lower in the 30 individuals with ASD compared with the 20 normal controls. The ABC scores were significantly increased in the ASD group compared with those of the control group. Thus, the results of the present study revealed that reduced plasma levels of AA and metabolites in association with high plasma EPA/AA ratios might down-regulate AA-related signaling mediators, such as Cp. Subsequently, reduced plasma Cp levels might reduce the protective capacity for brain damage, resulting in the pathophysiology underlying the behavioral symptoms in individuals with ASD. These findings suggest that reduced plasma AA levels may downregulate Cp. SN - 1872-7972 UR - https://www.unboundmedicine.com/medline/citation/26552013/Down_regulation_of_a_signaling_mediator_in_association_with_lowered_plasma_arachidonic_acid_levels_in_individuals_with_autism_spectrum_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(15)30244-5 DB - PRIME DP - Unbound Medicine ER -